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Copyright © 2009 JCBN Summary Our previous studies have demonstrated that lansoprazole inhibits acute inflam-
matory reactions as well as intestinal mucosal injuries induced by ischemia-reperfusion or
indomethacin administration in rats. Thus, proton pump inhibitors such as lansoprazole have
been demonstrated to prevent gastrointestinal mucosal injury by mechanisms independent of
acid inhibition. In our in vitro study, lansoprazole induced the expression of heme oxygenase-1
(HO-1) on rat gastric epithelial cells (RGM-1 cells), and exerted anti-inflammatory effect on
the dependent of HO-1 expression. Furthermore, NF-E2-related factor-2 (Nrf2) played an
important role in HO-1 expression induced by lansoprazole. In this review, we focused on
lansoprazole-induced HO-1 expression, its anti-inflammatory action, and the role of Nrf2 in its
expression.
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Introduction
Heme oxygenase (HO) is involved in heme catabolism,
a process in which the oxidation of heme leads to the
production of iron, biliverdin and carbon monoxide [1].
Three mammalian HO isozymes have been identified, one of
which, HO-1, is a stress-responsive protein. HO-1 is highly
inducible by a vast array of stimuli, including oxidative
stress, heat shock, ultraviolet radiation, ischemia-reperfusion,
heavy metals, bacterial lipopolysaccharide (LPS), cytokines,
nitric oxide, and its substrate, heme [2–5]. This strong
adaptive response of HO-1 to various stimuli suggests an
entirely new paradigm by which HO-1 could play a signifi-
cant role in protection against inflammatory processes and
oxidative tissue injury.
Recent studies have extensively investigated the transcrip-
tional factors and regulatory regions that are responsible for
induction of the ho-1 gene. Several signaling molecules
(e.g., mitogen-activated protein kinases (MAPK)) and
transcriptional regulators (activator protein-1, NF-E2-related
factor-2 (Nrf2), hypoxia-inducible factor-1 (HIF1) and
Bach-1) participate in the regulation of the ho-1 gene. In
these molecules, accumulating data implicate Nrf2 as a key
regulator of the adaptive response to oxidative stress [6–11]
and of the transcriptional activation of ho-1 [ 12]. Under
normal conditions, Nrf2 localizes in the cytoplasm, where it
interacts with Kelch-like ECH associating protein 1 (Keap1),
and is rapidly degraded by the ubiquitin-proteasome
pathway [13]. Namely, Keap1 acts as negative regulator of
Nrf2. Various stimuli, including electrophiles and oxidative
stress, liberate Nrf2 from Keap1, allowing Nrf2 to trans-
locate into the nucleus and to bind to antioxidant-response
elements (ARE) [14]. Nuclearly translocated Nrf2 provides
immediate transactivation of regulated encoding genes. In
this sequence of Nrf2 activation, the phosphorylation ofT. Takagi et al.
J. Clin. Biochem. Nutr.
10
Nrf2 is an important event in the dissociation of Nrf2 from
Keap1 [15–17]. Thus the translocation of Nrf2 is considered
a major defense mechanism that plays a key role in the
induction of HO-1.
In this review, we focused on the expression of HO-1
associated with Nrf2 pathway by lansoprazole.
Anti-inflammatory Effects by Lansoprazole
Proton pump inhibitors (PPIs) such as lansoprazole have
dramatically influenced the management of acid-peptic
disorders in recent years, and are extensively used to treat
acid-related disorders, including gastroesophageal reflux
disease and peptic ulcer disease caused by stress, non-
steroidal anti-inflammatory drugs and Helicobacter pylori
infection [18–21]. Lansoprazole is a strong anti-secretory
agent that acts on gastric H+/K+-adenosine triphosphatase
(H+/K+ ATPase) of parietal cells [22]. In addition to its
acid-suppressing effects, lansoprazole have been shown to
modulate the inflammatory status, reduce oxidative stress,
and ameliorate mucosal injuries in the esophagus [23, 24],
intestine [25, 26], and lung [27], in addition to the stomach
[28, 29]. It has been also demonstrated by in vitro studies
that lansoprazole inhibits the increased expression of vascular
adhesion molecules, the activation of neutrophils, and the
production of pro-inflammatory cytokines from activated
endothelial cells [30, 31]. We recently demonstrated using in
vivo models that lansoprazole inhibits acute inflammatory
reactions as well as intestinal mucosal injuries induced by
ischemia-reperfusion [25] or indomethacin administration in
rats [26]. These intestinal injuries induced by ischemia-
reperfusion or indomethacin were significantly inhibited by
lansoprazole at a dose of 5 mg/kg together with significant
suppression of the increased levels of thiobarbituric acid-
reactive substances, myeloperoxidase activities and cytokine-
induced neutrophil chemoattractant-1 (CINC-1) in the small
bowel. Furthermore, the increased CINC-1 mRNA expres-
sion after ischemia-reperfusion or indomethacin administra-
Fig. 1. The expression of HO-1 induced by lansoprazole.
RGM-1 cells were incubated with lansoprazole. (A) ho-1 gene expression was measured using real-time PCR. The mRNA level
of  β-actin was determined simultaneously, and HO-1/β-actin ratio was calculated for each sample. Values represent the
mean ± SEM (n =4 ) .  #p<0.05 compared to No stimulation (0 h) (B) Whole cell extracts were prepared and analyzed by
immunoblotting with an antibody against HO-1. (C) The expression and the localization of HO-1 in RGM-1 cells 6 h after
lansoprazole treatment was investigated using confocal microscopy.Lansoprazole Induced HO-1
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tion was also inhibited by the treatment with lansoprazole.
These results suggest that lansoprazole administered exo-
genously prevents the small intestine against ischemia-
reperfusion or indomethacin-induced damage, the action
being dependent on its anti-inflammatory and anti-oxidative
responses. These data indicate the possibility that lansopra-
zole may prevents intestinal mucosal injury by mechanisms
independent of acid inhibition.
HO-1 Expression Induced by Lansoprazole
Our recent study using a DNA microarray clearly showed
that lansoprazole induces several genes, including phase II
detoxifying enzyme (NADPH-ubiquinone oxidoreductase,
glutathione S-transferase) and antioxidant stress proteins
(HO-1, thioredoxin reductase, and superoxide dismutase)
in gastric epithelial cells (Naito, JCBN2007, http://www2.
kpu-m.ac.jp/%7Efirstmed/GeneChip.html) [32]. As shown in
Figure 1, we confirmed that lansoprazole induced HO-1
up-regulation in rat gastric epithelial cells. Incubation with
lansoprazole (1 μM) induced expression of the ho-1 gene
in the early phase within 3 h of lansoprazole addition. In
association with the induction of ho-1 gene expression, the
expression of the HO-1 protein was significantly increased
in a time-dependent manner after lansoprazole treatment,
and confocal microscopy revealed that the HO-1 protein
was localized to the cytoplasm fraction. Becker et al. [28]
also demonstrated that PPIs protect gastric epithelial cells
against oxidative stress, and this protection is abrogated in
the presence of an HO-1 inhibitor. Exposure to lansoprazole
resulted in a strong induction of HO-1 expression on mRNA
and protein level, and led to an increased activity of this
enzyme. These data indicate that lansoprazole-induced
HO-1 induction might account for the cytoprotective and
anti-inflammatory effects of lansoprazole independent of
acid-secretion inhibition.
Anti-Inflammatory Effect throughout HO-1 Induc-
tion by Lansoprazole
Rat CINC-1, a counterpart of the human growth-regulated
oncogene (GRO), has been suggested to participate in
neutrophil recruitment in an experimental model of gastritis
in rat. Our previous report demonstrated that rat gastric
epithelial cells (RGM-1 cells) produced CINC-1 in response
to various pro-inflammatory cytokines, such as TNF-α, IL-
1β, and bacterial LPS [30]. To confirm the anti-inflammatory
effect of lansoprazole-induced HO-1 on RGM-1 cells, we
measured the production of CINC-1 on RGM-1 cells using
ELISA. As shown in Table 1, pretreatment with lansoprazole
significantly inhibited the production of CINC-1 from
stimulated RGM-1 cells with IL-1β. In addition, the inhibi-
tion was reversed by co-treatment with the HO-1 inhibitor
SnPP. These data indicate that the anti-inflammatory effect
of lansoprazole is mediated through the induction of HO-1.
On this basis, the up-regulation of HO-1 by lansoprazole
contributes to the inhibition of chemokine production from
stimulated gastric mucosal cells.
Role of Nrf2 in HO-1 Up-Regulation by Lansoprazole
We used a small interfering RNA (siRNA) approach to
determine if lansoprazole-mediated up-regulation of HO-1
was dependent on Nrf2 in RGM-1 cells. RGM-1 cells were
transiently transfected with either control siRNA or siRNA
directed against Nrf2. Thirty hour after transfection, cells
were exposed to lansoprazole for 6 h, and then ho-1 mRNA
and HO-1 protein expression were examined by real-time
PCR and Western blotting, respectively. Under these condi-
tions, the treatment of RGM-1 cells with Nrf2-siRNA
decreased the constitutive ho-1 mRNA level and abolished
the lansoprazole-induced ho-1 mRNA (Table 2) and HO-1
protein expression, suggesting a pivotal role of Nrf2 in the
regulation of HO-1 in RGM-1 cells. These experiments
demonstrate a direct correlation between Nrf2 and HO-1
expression and support the contention that lansoprazole-
mediated up-regulation of HO-1 is Nrf2-dependent.
Table 1. The inhibition of CINC-1 production in RGM-1 cells
treated with lansoprazole
Data represent the mean + SEM (n =3 ) .  * p<0.05 compared to




Normal 13.4 ± 0.08
IL-1β (1 ng/ml) 48.7 ± 8.72*
IL-1β (1 ng/ml) + Lansoprazole 1 μM 22.7 ± 1.21#
IL-1β (1 ng/ml) + Lansoprazole 1 μM
+ SnPP 1 μM
46.6 ± 4.71
Table 2. The effect of Nrf2-siRNA on HO-1 expression
Data represent the mean + SEM (n =3 ) .  * p<0.05 compared to
normal group. #p<0.05 compared to Lansoprazole 1 μM (Control
RNAi) group.
Treatment
HO-1 mRNA expression 
(HO-1/β-actin)
Normal (Control RNAi) 1
Lansoprazole 1 μM (Control RNAi) 1.62 ± 0.08*
Nrf2 RNAi 0.85 ± 0.08
Nrf2 RNAi + Lansoprazole 1 μM1 . 1 9 ± 0.04#T. Takagi et al.
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Conclusion
In summary, lansoprazole up-regulated HO-1 expression
throughout Nrf2 in rat gastric epithelial cells, and the up-
regulated HO-1 had anti-inflammatory effects (Fig. 2) [33].
Further studies will be needed to clarify the mechanisms
involved in this phenomenon in greater detail.
Abbreviations
PPI, proton pump inhibitor; HO-1, heme oxygenase-1;
MAPK, mitogen-activated protein kinases; Nrf2, NF-E2-
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